Management

Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of APIM Therapeutics AS and Nextera AS. Born 1961.

Shareholding: 22,400

Conditional Employee Options: Option program 2019/2025: 1,108,095 Option program 2022/2024: 38,000 Option program 2023/2025: 18,000

Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá), and holds a PhD from the Institut Pasteur/Université Paris 7. Employed since 2017. He has performed academic work at the Pasteur Institut and the University of California, San Francisco on cancer immunotherapy. Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956.

Shareholding: 3,009

Conditional Employee Options: Option program 2019/2025: 772,776 Option program 2022/2024: 19,000 Option program 2023/2025: 9,000

Has 25 years’ of experience in capital markets and corporate strategy experience. Employed since 2024. Before joining BioInvent, he served as Managing Director at LifeSci Advisors, where he established a Life Sci office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist, sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President at Lehman Brothers in the ECM division. Born 1977.

Shareholding: -

Conditional employee options: -

Doctor of Immunology. Employed since 2001. Frequent publisher in leading scientific immunology journals, and speaker and chair at international Immuno-oncology conferences. Inventor on more than 150 patents and patent applications. Visiting Professor at University of Southampton. Born 1973.

Shareholding: 23,089 (own and affiliated holdings)

Conditional Employee Options: Option program 2019/2025: 664,857 Option program 2022/2024: 19,000 Option program 2023/2025: 9,000

Master of Science in Chemical engineering. Employed since 2016 and is responsible for process development and production of antibodies for clinical studies. He has 20 years of experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S (now AGC Biologics), DAKO A/S and Symphogen A/S. Born 1974.

Shareholding: 22,303 (whereof 7,177 in endowment insurance)

Conditional Employee Options: Option program 2019/2025: 353,259 Option program 2022/2024: 19,000 Option program 2023/2025: 9,000

Over 25 years’ experience of transforming international organizations, with expertise in regulatory affairs and building businesses focusing on drug development. Employed 2022. Chair of the board of Aidee Health and a jury panelist of the European Innovation Council (EIC) which supports innovation, from early-stage research to startups and scaleups with a special focus on breakthrough, market-creating and deep-tech innovations. Former Executive Vice President, International Operations & Early Development at the Norwegian company LINK Medical Research. She previously spent more than 20 years with Theradex Oncology as Director, Clinical and Regulatory Operations for Europe. Born 1968.

Shareholding: -

Conditional Employee Options: Option program 2022/2024: 19,000 Option program 2023/2025: 9,000

MBA, Lund University. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. Previous experience from the Swedish Tax Agency and as auditor at PricewaterhouseCoopers. Born 1963.

Shareholding: 8,000

Conditional Employee Options: Option program 2019/2025: 347,055 Option program 2022/2024: 19,000 Option program 2023/2025: 9,000

PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, US. Employed since 2022.

Over 20 years of experience in business development, alliance management, and corporate strategy. Sylvie has served in key positions at Serono, Merck KGaA, and Index Ventures as well as McKinsey and Company and the Harvard Business School. Born 1965.

Shareholding: 22,870 (own and affiliated holdings)

Conditional Employee options: -

PhD in Biology from the University of Oslo. Employed since 2023.

Experienced regulatory affairs leader who has worked across all stages of product development and has hands-on experience of the US and EU regulatory systems. 

Previously Vice President and Head of Regulatory Affairs at Circio, Head of Regulatory Affairs at Nordic Nanovector and also held senior regulatory positions at Photocure and Nycomed/GE Healthcare. Born 1965.

Shareholding: -

Conditional employee options: Option program 2023/2025: 4,741